相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
Michael F. Leahy et al.
BLOOD (2011)
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
Ajay K. Gopal et al.
BLOOD (2008)
What is triple-negative breast cancer?
William J. Irvin et al.
EUROPEAN JOURNAL OF CANCER (2008)
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice
Heather A. Jacene et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Prognostic markers in triple-negative breast cancer
Emad A. Rakha et al.
CANCER (2007)
Update of carcinoembryonic antigen radioimmunotherapy with (131)supercript stopI-Labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group
Torsten Liersch et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ
Martin Goette et al.
BREAST CANCER RESEARCH (2007)
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
Bruce G. Haffty et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma
Michael F. Leahy et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, non-clathrin-mediated pathway
Larissa C. Wilsie et al.
LIPIDS IN HEALTH AND DISEASE (2006)
Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype
Fusun Baba et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis
Lars Jakobsson et al.
DEVELOPMENTAL CELL (2006)
Syndecan-1 expression by stromal. broblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis
T Maeda et al.
ONCOGENE (2006)
Therapeutic value of glycosaminoglycans in cancer
George W. Yip et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis
Neta Ilan et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/Mage3 complex density using a high-affinity TCR like monoclonal antibody
K Bernardeau et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel
SV Govindan et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours
D Mennerich et al.
EUROPEAN JOURNAL OF CANCER (2004)
The syndecan-1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cells
DLM Beauvais et al.
JOURNAL OF CELL BIOLOGY (2004)
Prognostic value of syndecan-1 expression in breast cancer
M Leivonen et al.
ONCOLOGY (2004)
High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis
M Barbareschi et al.
CANCER (2003)
Syndecan-1 accumulates in lysosomes of poorly differentiated breast carcinoma cells
BJ Burbach et al.
MATRIX BIOLOGY (2003)
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma
PWB Derksen et al.
BLOOD (2002)
分享论文
